Methotrexate for Severe Vulvar Lichen Sclerosus

Summary

Vulvar lichen sclerosus is a chronic inflammatory skin disease affecting the vulva and genital region, which may cause intense pruritus, pain, burning sensations, and progressive scarring. In severe cases, the disease may lead to significant anatomical changes, sexual dysfunction, and a reduction in quality of life. First-line treatment for vulvar lichen sclerosus consists of high-potency topical corticosteroids. Although many patients experience symptom relief, a considerable number of women continue to have persistent symptoms or progressive anatomical damage. For these patients, therapeutic options are limited. MTX is an immunomodulatory medication that has been used for several decades in the treatment of inflammatory and autoimmune diseases. Previous clinical observations suggest that MTX may be beneficial for patients with severe or treatment-resistant vulvar lichen sclerosus; however, prospective clinical studies in this population remain scarce. This prospective, open-label, phase II pilot study aims to evaluate the efficacy and safety of subcutaneous injectable MTX, administered once weekly at a standardized initial dose of 12.5 mg, in women with severe vulvar lichen sclerosus who have not responded adequately to standard topical therapy. Participants will receive treatment for 12 months, with regular clinical and laboratory monitoring. The primary objective of the study is to assess whether treatment with MTX leads to improvement in symptoms and stabilization of vulvar skin changes, using patient-reported outcome measures and standardized clinical assessments. Secondary objectives include evaluation of treatment tolerability, adherence, and the occurrence of adverse events. As a pilot study, this research is designed to generate preliminary data on feasibility, safety, and potential clinical benefit, which may guide future larger controlled studies and contribute to the development of evidence-based therapeutic strategies for women with severe vulvar lichen sclerosus.

Timeline

Start

2026-01-21

Primary completion

2027-01

Completion

2027-01

Publications

• Background Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4:287-291.
• Background Jasionowska S, Almadori A, Goble M, Langridge BJ, Iakovou D, Kamel F, McKenzie M, Mclean A, Boyle D, Zenner N, Swale V, Butler PEM. A systematic review of outcome measures evaluating treatment efficacy in vulval lichen sclerosus and evaluation of patients' priorities. Skin Health Dis. 2024 Jul 5;4(5):e422. doi: 10.1002/ski2.422. eCollection 2024 Oct.
• Background Saunderson RB, Harris V, Yeh R, Mallitt KA, Fischer G. Vulvar quality of life index (VQLI) - A simple tool to measure quality of life in patients with vulvar disease. Australas J Dermatol. 2020 May;61(2):152-157. doi: 10.1111/ajd.13235. Epub 2020 Jan 27.
• Background Gunthert AR, Duclos K, Jahns BG, Krause E, Amann E, Limacher A, Mueller MD, Juni P. Clinical scoring system for vulvar lichen sclerosus. J Sex Med. 2012 Sep;9(9):2342-50. doi: 10.1111/j.1743-6109.2012.02814.x. Epub 2012 Jul 3.
• Background Ghafari-Saravi A, Foster E. Treatment of Refractory Vulvar Lichen Sclerosus With Methotrexate. J Low Genit Tract Dis. 2024 Apr 1;28(2):202-204. doi: 10.1097/LGT.0000000000000795. Epub 2024 Jan 10.
• Background Cuellar-Barboza A, Bashyam AM, Ghamrawi RI, Aickara D, Feldman SR, Pichardo RO. Methotrexate for the treatment of recalcitrant genital and extragenital lichen sclerosus: A retrospective series. Dermatol Ther. 2020 Jul;33(4):e13473. doi: 10.1111/dth.13473. Epub 2020 Jun 23. No abstract available.
• Background Urun M, Gursel Urun Y, Sarikaya Solak S. A case of extragenital linear lichen sclerosus along the lines of Blaschko responding to methotrexate. Acta Dermatovenerol Alp Pannonica Adriat. 2020 Sep;29(3):149-151.
• Background Kreuter A, Tigges C, Gaifullina R, Kirschke J, Altmeyer P, Gambichler T. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. Arch Dermatol. 2009 Nov;145(11):1303-8. doi: 10.1001/archdermatol.2009.235.
• Background Nayeemuddin F, Yates VM. Lichen sclerosus et atrophicus responding to methotrexate. Clin Exp Dermatol. 2008 Aug;33(5):651-2. doi: 10.1111/j.1365-2230.2008.02721.x. Epub 2008 May 27. No abstract available.
• Background Warren RB, Weatherhead SC, Smith CH, Exton LS, Mohd Mustapa MF, Kirby B, Yesudian PD. British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016 Jul;175(1):23-44. doi: 10.1111/bjd.14816. No abstract available.
• Background Nguyen BT, Kraus CN. Vulvar Lichen Sclerosus: What's New? Cutis. 2024 Mar;113(3):104-106. doi: 10.12788/cutis.0967. No abstract available.
• Background Hargis A, Ngo M, Kraus CN, Mauskar M. Systemic Therapy for Lichen Sclerosus: A Systematic Review. J Low Genit Tract Dis. 2024 Jan 1;28(1):84-90. doi: 10.1097/LGT.0000000000000775. Epub 2023 Nov 4.
• Background Singh N, Mishra N, Ghatage P. Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review. Cureus. 2021 Feb 24;13(2):e13527. doi: 10.7759/cureus.13527.

Drugs

Indications